Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Market Snapshot: Under Pressure, Insulin Makers Pin Hopes On New Products

Executive Summary

Bevy of new products like Novo Nordisk’s Tresiba offer some incremental improvements over older insulins, but in an increasingly crowded market, payers have the upper hand.

You may also be interested in...



UnitedHealthcare Prefers Basaglar Biosimilar At Lantus' Expense

UnitedHealthcare's decision to exclude Lantus in favor of Basaglar begs the question of how low biosimilar pricing will go, amid soaring diabetes costs.

Lilly and Boehringer Ingelheim Launch Biosimilar Lantus In UK, Germany

The cost of biosimilar Lantus to payers is at around a 15% discount to the originator product in the UK, but cost-savings are expected to vary across Europe as supply contracts with health insurers and hospitals are negotiated.

Sanofi Board Forces CEO Chris Viehbacher to Resign Amid Lantus Woes

Sanofi announced that Christopher Viehbacher has resigned as CEO after its board voted unanimously to remove him. The drama comes amid serious worries over the group’s cash cow medicine, Lantus.

Topics

Related Companies

UsernamePublicRestriction

Register

PS057176

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel